Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
39.84
+0.30 (0.76%)
At close: Nov 26, 2025, 4:00 PM EST
39.96
+0.12 (0.30%)
After-hours: Nov 26, 2025, 7:22 PM EST
Royalty Pharma Revenue
Royalty Pharma had revenue of $609.29M in the quarter ending September 30, 2025, with 7.90% growth. This brings the company's revenue in the last twelve months to $2.35B, up 3.70% year-over-year. In the year 2024, Royalty Pharma had annual revenue of $2.26B, down -3.86%.
Revenue (ttm)
$2.35B
Revenue Growth
+3.70%
P/S Ratio
7.36
Revenue / Employee
$23,735,798
Employees
99
Market Cap
23.00B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.26B | -90.98M | -3.86% |
| Dec 31, 2023 | 2.35B | 117.34M | 5.24% |
| Dec 31, 2022 | 2.24B | -52.25M | -2.28% |
| Dec 31, 2021 | 2.29B | 167.11M | 7.87% |
| Dec 31, 2020 | 2.12B | 308.10M | 16.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
RPRX News
- 1 day ago - Royalty Pharma to Present at Upcoming Investor Conferences - GlobeNewsWire
- 12 days ago - Royalty Pharma: Guidance Raised Again, Platform Strength Intact -- Buy Reiterated - Seeking Alpha
- 21 days ago - Royalty Pharma plc (RPRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Royalty Pharma Reports Third Quarter 2025 Results - GlobeNewsWire
- 23 days ago - Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences - GlobeNewsWire
- 5 weeks ago - Royalty Pharma Declares Fourth Quarter 2025 Dividend - GlobeNewsWire
- 6 weeks ago - Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire
- 2 months ago - Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - GlobeNewsWire